Front Runners: BioTelemetry (BEAT), Outerwall Inc. (OUTR), Amicus Therapeutics, Inc. (FOLD), Five Prime Therapeutics (FPRX), Apple (AAPL)

In a report published Monday, analysts at Avondale upgraded their rating on the shares of BioTelemetry, Inc. (BEAT) to ‘Market Perform’. The target price has been set to $15.00 from $8.00 implying 72% expected return. BioTelemetry’s shares closed at $8.11 Friday.

BEAT is trading at unusually high volume Monday with 415K shares changing hands. It is already at 2x its average daily volume and trading up nearly 8% at $8.74.

BioTelemetry, Inc has a forward PE of 39.59. Price/Sales for the t-12 period is 1.47, while EPS is ($0.31). The company has a market cap of $233M and is part of the healthcare sector and specialized health hervices industry. Shares are down 18% year-over-year ; up 10% year-to-date.

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and cardiac core laboratory services. The company is headquartered in Malvern, Pennsylvania.

Shares of Outerwall Inc. (OUTR) are up almost 8.56% to $68.99 in midday trading Monday after the company announced new daily rental prices for DVDs, Blu-ray Discs and video game discs in the U.S.

Outerwall said in a press release that starting next week, the daily rental rate for DVDs will increase from $1.20 to $1.50, and the daily rental rate for a Blu-ray Disc will increase from $1.50 to $2. Beginning January 6, the daily rental rate for video games will increase from from $2.00 to $3.00. Outerwall also said the new prices were chosen after several months of market testing,

OUTR, currently valued at $1.26B, has a median Wall Street price target of $70.00 with a high target of $82.00. Approximately 1.33M shares have already changed hands, compared to the stock’s average daily volume of 503.25K.

In the past 52 weeks, shares of Bellevue, Wa.-based retail solutions provider have traded between a low of $51.17 and a high of $74.30 with the 50-day MA and 200-day MA located at $58.73 and $60.58 levels, respectively. Additionally, shares of OUTR trade at a P/E ratio of 0.59 and have a Relative Strength Index (RSI) and MACD indicator of 73.33 and +1.90, respectively.

OUTR currently prints a one year loss of about 6.00%, and a year-to-date loss of around 5.52%.

Shares of Amicus Therapeutics, Inc. (FOLD) are up 11.63% to $7.77 in midday trading. The move comes on a big volume too with the issue currently trading more than 3.1 million shares, which dwarfs the average volume of 2.04 million. Not seeing any news or rumors to account for the move.

Amicus Therapeutics is a Cranbury, New Jersey-based biopharmaceutical company. Its stock has a median consensus analyst price target of $9.00 with a high target of $14.00, and a 52-week trading range of $1.77 to $7.87.

The T-12 price/sales at Amicus Therapeutics is 356.89. FOLD‘s revenue for the same period is $1.55 million.

Amicus Therapeutics, Inc has market cap of $615.53M.

Five Prime Therapeutics (FPRX) shares have moved 18% higher intraday following an announcement that the company has entered into an exclusive clinical collaboration agreement with Bristol-Myers Squibb.

FPRX recently gained $3.11 to $18.86. Shares of South San Francisco, Calif.-based firm have risen 105.87% year-over-year and 63.39% year-to-date.

Apple Inc (AAPL) price target has been raised from $120.00 to $135.00 by Susquehanna analysts, according to a research note published on Monday. Susquehanna analysts maintained their Positive rating on the company saying that their “checks” suggest that Apple “is producing as much of the iPhone 6 Plus as they can” but that “iPhone demand is still exceeding supply.”

Susquehanna’s new price target represents a potential upside of 14% from Apple’s current PPS. AAPL recently gained $1.74 to $118.21.

In other Apple news this morning, KGI Research’s Ming-Chi Kuo, one of the few analysts with a respectable record on Apple forecasts, said he expects Cupertino to sell 71.5M iPhone units in 4Q’14, followed by sub-50M to start 2015.

Be the first to comment

Leave a Reply

Your email address will not be published.


*